Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sao Tome and Principe Health Report.
Press releases published on October 14, 2025
Gainwell Technologies Launches Rural Health Transformation Collaborative
IRVING, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gainwell Technologies (Gainwell), a leading innovator in healthcare technology and Medicaid modernization, announced the launch of the Gainwell Rural Health Transformation Collaborative—a nationwide …
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings …
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified stem cell therapy under Florida statute (§ 458.3245), …
Vireo Growth Inc. Announces Closing of Acquisition of Outstanding Senior Secured Convertible Notes of Schwazze
– Parties enter into Restructuring Support Agreement; Vireo to bid to acquire control of Schwazze assets – – Schwazze operates 63 dispensaries and 10 manufacturing facilities in Colorado and New Mexico – MINNEAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vireo …
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout his career, Dr. …
FibroBiologics to Present at the 2025 ThinkEquity Conference
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Counterpart Health Expands Proven Flywheel for HEDIS Excellence to Third-Party Partners
SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered value-based care …
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod …
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year HINGHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- …
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation …
As "Uptober" Ignites Crypto Market, Bonk, Inc. Revs Up Its Revenue-Generating Engine
Company to Capitalize on its Position as the Most Widely Held Token on Solana and a Historically Strong Q4 for Digital Assets SCOTTSDALE, AZ, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Bonk, Inc. (Nasdaq: BNKK) (the “Company”), following its recent corporate …
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the …
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established plans to accelerate patient …
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to address the condition HORSHAM, Pa., Oct …
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
$50 million drawn down at closing, with access to up to an additional $80 million Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) Provides non-dilutive capital and …
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual Acuity (BCDVA) at …
R1 to Acquire Phare Health, a Leading AI Platform for Automating Inpatient Coding and Pre-Bill Clinical Documentation Improvement
MURRAY, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), an industry leader in managing and intelligently automating healthcare revenue management, today announced that it has entered into an agreement to acquire Phare Health Ltd, a …